Elevated expression of HDAC6 in clinical peritoneal dialysis patients and its pathogenic role on peritoneal angiogenesis

References

• Khan S, Rosner MH. Peritoneal dialysis for patients with end-stage renal disease and liver cirrhosis. Perit Dial Int. 2018;38(6):397–401.
   PubMed Web of Science ®Google Scholar
• Mehrotra R, Devuyst O, Davies SJ, et al. The current state of peritoneal dialysis. J Am Soc Nephrol. 2016;27(11):3238–3252.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Jiang N, Ni Z. Strategies for preventing peritoneal fibrosis in peritoneal dialysis patients: new insights based on peritoneal inflammation and angiogenesis. Front Med. 2017;11(3):349–358.
   PubMed Web of Science ®Google Scholar
• Strippoli R, Moreno-Vicente R, Battistelli C, et al. Molecular mechanisms underlying peritoneal EMT and fibrosis. Stem Cells Int. 2016;2016:3543678.
   PubMed Web of Science ®Google Scholar
• Kim YL. Update on mechanisms of ultrafiltration failure. Perit Dial Int. 2009;29(2):S123–S127.
   PubMedGoogle Scholar
• Lai KN, Leung JC, Chan LY, et al. Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products. Clin Exp Immunol. 2004;138(3):466–475.
   PubMed Web of Science ®Google Scholar
• Liu J, Wu X, Liu Y, et al. High-glucose-based peritoneal dialysis solution induces the upregulation of VEGF expression in human peritoneal mesothelial cells: the role of pleiotrophin. Int J Mol Med. 2013;32(5):1150–1158.
   PubMed Web of Science ®Google Scholar
• Witowski J, Kamhieh-Milz J, Kawka E, et al. IL-17 in peritoneal dialysis-associated inflammation and angiogenesis: conclusions and perspectives. Front Physiol. 2018;9:1694.
   PubMed Web of Science ®Google Scholar
• Ye EA, Steinle JJ. miR-146a suppresses STAT3/VEGF pathways and reduces apoptosis through IL-6 signaling in primary human retinal microvascular endothelial cells in high glucose conditions. Vision Res. 2017;139:15–22.
   PubMed Web of Science ®Google Scholar
• Lin CM, Shyu KG, Wang BW, et al. Chrysin suppresses IL-6-induced angiogenesis via down-regulation of JAK1/STAT3 and VEGF: an in vitro and in ovo approach. J Agric Food Chem. 2010;58(11):7082–7087.
   PubMed Web of Science ®Google Scholar
• Padwal M, Cheng G, Liu L, et al. WNT signaling is required for peritoneal membrane angiogenesis. Am J Physiol Renal Physiol. 2018;314(6):F1036–F1045.
   PubMed Web of Science ®Google Scholar
• Tanabe K, Maeshima Y, Ichinose K, et al. Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model. Kidney Int. 2007;71(3):227–238.
   PubMed Web of Science ®Google Scholar
• Yoshio Y, Miyazaki M, Abe K, et al. TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int. 2004;66(4):1677–1685.
   PubMed Web of Science ®Google Scholar
• Shi Y, Tao M, Wang Y, et al. Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis. J Pathol. 2020;250(1):79–94.
   PubMed Web of Science ®Google Scholar
• Kariya T, Nishimura H, Mizuno M, et al. TGF-beta1-VEGF-A pathway induces neoangiogenesis with peritoneal fibrosis in patients undergoing peritoneal dialysis. Am J Physiol Renal Physiol. 2018;314(2):F167–F180.
   PubMed Web of Science ®Google Scholar
• Zweers MM, Struijk DG, Smit W, et al. Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up. J Lab Clin Med. 2001;137(2):125–132.
   PubMed Web of Science ®Google Scholar
• Lopes Barreto D, Krediet RT. Current status and practical use of effluent biomarkers in peritoneal dialysis patients. Am J Kidney Dis. 2013;62(4):823–833.
   PubMed Web of Science ®Google Scholar
• Catar R, Witowski J, Zhu N, et al. IL-6 trans-signaling links inflammation with angiogenesis in the peritoneal membrane. J Am Soc Nephrol. 2017;28(4):1188–1199.
   PubMed Web of Science ®Google Scholar
• Yang X, Yan H, Jiang N, et al. IL-6 trans-signaling drives a STAT3-dependent pathway that leads to structural alterations of the peritoneal membrane. Am J Physiol Renal Physiol. 2020;318(2):F338–F353.
   PubMed Web of Science ®Google Scholar
• Xiao J, Gong Y, Chen Y, et al. IL-6 promotes epithelial-to-mesenchymal transition of human peritoneal mesothelial cells possibly through the JAK2/STAT3 signaling pathway. Am J Physiol Renal Physiol. 2017;313(2):F310–F318.
   PubMed Web of Science ®Google Scholar
• Lopes Barreto D, Coester AM, Noordzij M, et al. Variability of effluent cancer antigen 125 and interleukin-6 determination in peritoneal dialysis patients. Nephrol Dial Transplant. 2011;26(11):3739–3744.
   PubMed Web of Science ®Google Scholar
• Krediet RT. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int. 2001;21(6):560–567.
   PubMed Web of Science ®Google Scholar
• Cheema H, Bargman JM. Cancer antigen 125 as a biomarker in peritoneal dialysis: mesothelial cell health or death? Perit Dial Int. 2013;33(4):349–352.
   PubMed Web of Science ®Google Scholar
• Tamura R, Doi S, Nakashima A, et al. Inhibition of the H3K4 methyltransferase SET7/9 ameliorates peritoneal fibrosis. PLoS One. 2018;13(5):e0196844.
   PubMed Web of Science ®Google Scholar
• Wang Q, Xu L, Zhang X, et al. GSK343, an inhibitor of EZH2, mitigates fibrosis and inflammation mediated by HIF-1alpha in human peritoneal mesothelial cells treated with high glucose. Eur J Pharmacol. 2020;880:173076.
   PubMed Web of Science ®Google Scholar
• Shen Y, Wei W, Zhou DX. Histone acetylation enzymes coordinate metabolism and gene expression. Trends Plant Sci. 2015;20(10):614–621.
   PubMed Web of Science ®Google Scholar
• Khangura RK, Bali A, Jaggi AS, et al. Histone acetylation and histone deacetylation in neuropathic pain: an unresolved puzzle? Eur J Pharmacol. 2017;795:36–42.
   PubMed Web of Science ®Google Scholar
• Guo P, Chen W, Li H, et al. The histone acetylation modifications of breast cancer and their therapeutic implications. Pathol Oncol Res. 2018;24(4):807–813.
   PubMed Web of Science ®Google Scholar
• Ke B, Chen Y, Tu W, et al. Inhibition of HDAC6 activity in kidney diseases: a new perspective. Mol Med. 2018;24(1):33.
   PubMedGoogle Scholar
• Saito S, Zhuang Y, Shan B, et al. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway. PLoS One. 2017;12(10):e0186615.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao L, Jiao FZ, et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid alleviates liver fibrosis by suppressing the transforming growth factor-beta1 signal pathway. Hepatobiliary Pancreat Dis Int. 2018;17(5):423–429.
   PubMed Web of Science ®Google Scholar
• Yuan LL, Wang F, Li SL, et al. Effects of downregulation of HDAC6 expression on cell cycle, proliferation and migration of laryngeal squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi. 2012;34(6):430–435.
   PubMedGoogle Scholar
• Xu L, Liu N, Gu H, et al. Histone deacetylase 6 inhibition counteracts the epithelial-mesenchymal transition of peritoneal mesothelial cells and prevents peritoneal fibrosis. Oncotarget. 2017;8(51):88730–88750.
   PubMedGoogle Scholar
• Zhou X, Zang X, Ponnusamy M, et al. Enhancer of zeste homolog 2 inhibition attenuates renal fibrosis by maintaining Smad7 and phosphatase and tensin homolog expression. J Am Soc Nephrol. 2016;27(7):2092–2108.
   PubMed Web of Science ®Google Scholar
• Pang M, Kothapally J, Mao H, et al. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol. 2009;297(4):F996–F1005.
   PubMed Web of Science ®Google Scholar
• Aufricht C, Beelen R, Eberl M, et al. Biomarker research to improve clinical outcomes of peritoneal dialysis: consensus of the European Training and Research in Peritoneal Dialysis (EuTRiPD) network. Kidney Int. 2017;92(4):824–835.
   PubMed Web of Science ®Google Scholar
• Redahan L, Davenport A. Peritoneal dialysate effluent and serum CA125 concentrations in stable peritoneal dialysis patients. J Nephrol. 2016;29(3):427–434.
   PubMed Web of Science ®Google Scholar
• Pecoits-Filho R, Barany P, Lindholm B, et al. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant. 2002;17(9):1684–1688.
   PubMed Web of Science ®Google Scholar
• Catar R, Witowski J, Wagner P, et al. The proto-oncogene c-Fos transcriptionally regulates VEGF production during peritoneal inflammation. Kidney Int. 2013;84(6):1119–1128.
   PubMed Web of Science ®Google Scholar
• Catar RA, Chen L, Cuff SM, et al. Control of neutrophil influx during peritonitis by transcriptional cross-regulation of chemokine CXCL1 by IL-17 and IFN-γ. J Pathol. 2020;251(2):175–186.
   PubMed Web of Science ®Google Scholar
• Yang X, Zhang H, Hang Y, et al. Intraperitoneal interleukin-6 levels predict peritoneal solute transport rate: a prospective cohort study. Am J Nephrol. 2014;39(6):459–465.
   PubMed Web of Science ®Google Scholar
• Loeffler S, Fayard B, Weis J, et al. Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer. 2005;115(2):202–213.
   PubMed Web of Science ®Google Scholar
• Li A, Chen P, Leng Y, et al. Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway. Oncogene. 2018;37(45):5952–5966.
   PubMed Web of Science ®Google Scholar
• Lienlaf M, Perez-Villarroel P, Knox T, et al. Essential role of HDAC6 in the regulation of PD-L1 in melanoma. Mol Oncol. 2016;10(5):735–750.
   PubMed Web of Science ®Google Scholar
• Padwal M, Liu L, Margetts PJ. The role of WNT5A and Ror2 in peritoneal membrane injury. J Cell Mol Med. 2020;24(6):3481–3491.
   PubMed Web of Science ®Google Scholar
• Khan FU, Owusu-Tieku NYG, Dai X, et al. Wnt/β-catenin pathway-regulated fibromodulin expression is crucial for breast cancer metastasis and inhibited by aspirin. Front Pharmacol. 2019;10:1308.
   PubMed Web of Science ®Google Scholar
• Wang SH, Li N, Wei Y, et al. β-catenin deacetylation is essential for WNT-induced proliferation of breast cancer cells. Mol Med Rep. 2014;9(3):973–978.
   PubMed Web of Science ®Google Scholar